Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
The content of urokinase- and tissue-type plasminogen activators and plasminogen activator inhibitor PAI-1 in the cytosol of primary and metastatic melanomas and benign skin pigment neoplasms was estimated by enzyme immunoassay. It was shown that local growth and invasion of melanomas are related to suppressed expression of tissue plasminogen activator. The content of urokinase plasminogen activator increases in patients with distant metastases and large thickness of the primary tumor.
Gershtein
E S
ES
N. N. Blokhin Russian Oncology Research Center, Russian Academy of Medical Sciences, Moscow.
Medvedeva
S V
SV
Babkina
I V
IV
Kushlinskii
N E
NE
Trapeznikov
N N
NN
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology / Q000556:secondary; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D015842:Serine Proteinase Inhibitors / Q000378:metabolism; D012878:Skin Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D013223:Statistics as Topic; D010959:Tissue Plasminogen Activator / Q000378:metabolism*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator